Aberrant hyperediting of the myeloma transcriptome by ADAR1 confers oncogenicity and is a marker of poor prognosis-Reference-Cited by-同舟云学术

Aberrant hyperediting of the myeloma transcriptome by ADAR1 confers oncogenicity and is a marker of poor prognosis

Published:2018-09-20 Issue:12 Volume:132 Page:1304-1317
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Teoh Phaik Ju¹^ORCID,An Omer¹^ORCID,Chung Tae-Hoon¹,Chooi Jing Yuan¹,Toh Sabrina H. M.¹,Fan Shuangyi²³,Wang Wilson⁴⁵,Koh Bryan T. H.⁴^ORCID,Fullwood Melissa J.¹^ORCID,Ooi Melissa G.⁶⁷⁸^ORCID,de Mel Sanjay⁶⁸,Soekojo Cinnie Y.⁶⁸,Chen Leilei¹⁹^ORCID,Ng Siok Bian²³^ORCID,Yang Henry¹,Chng Wee Joo¹⁶⁷⁸^ORCID

Affiliation:

1. Cancer Science Institute of Singapore, National University of Singapore, Singapore;

2. Department of Pathology, National University Hospital, National University Health System, Singapore;

3. Department of Pathology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore;

4. Department of Orthopaedic Surgery, National University Hospital, Singapore;

5. Department of Orthopedic Surgery, Yong Loo Lin School of Medicine, National University of Singapore, Singapore;

6. National University Cancer Institute, Singapore;

7. Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore;

8. Department of Haematology-Oncology, National University Cancer Institute of Singapore, National University Health System, Singapore; and

9. Department of Anatomy, Yong Loo Lin School of Medicine, National University of Singapore, Singapore

Abstract

Key Points The integrity of the MM transcriptome is compromised by ADAR1 overexpression, conferring oncogenic events in an editing-dependent manner. NEIL1 is an important ADAR1 editing target, and its recoded protein has a defective functional capacity and gain-of-function properties.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/132/12/1304/1467485/blood832576.pdf

Reference35 articles.

1. Genomics in multiple myeloma: biology and clinical implications;Chng;Pharmacogenomics,2005

2. p53 haploinsufficiency and functional abnormalities in multiple myeloma;Teoh;Leukemia,2014

3. Recent progress in relapsed multiple myeloma therapy: implications for treatment decisions;Moreau;Br J Haematol,2017

4. Current and emerging treatment options for patients with relapsed myeloma;Castelli;Clin Med Insights Oncol,2013

5. Next-generation sequencing in multiple myeloma: insights into the molecular heterogeneity of the disease;Agnelli;Int J Hematol Oncol,2014

Cited by 67 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. RNA processing mechanisms contribute to genome organization and stability in B cells;Oncogene;2024-01-29

2. The role of ADAR1 through and beyond its editing activity in cancer;Cell Communication and Signaling;2024-01-17

3. Approach to High-Risk Multiple Myeloma;Hematology/Oncology Clinics of North America;2024-01

4. Harnessing ADAR-Mediated Site-Specific RNA Editing in Immune-Related Disease: Prediction and Therapeutic Implications;International Journal of Molecular Sciences;2023-12-26

5. Utilizing AAV-mediated LEAPER 2.0 for programmable RNA editing in non-human primates and nonsense mutation correction in humanized Hurler syndrome mice;Genome Biology;2023-10-23